1. Home
  2. PZZA vs XERS Comparison

PZZA vs XERS Comparison

Compare PZZA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Papa John's International Inc.

PZZA

Papa John's International Inc.

HOLD

Current Price

$34.80

Market Cap

1.2B

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.31

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZZA
XERS
Founded
1984
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
PZZA
XERS
Price
$34.80
$6.31
Analyst Decision
Buy
Buy
Analyst Count
8
6
Target Price
$45.00
$10.83
AVG Volume (30 Days)
665.1K
1.2M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
5.25%
N/A
EPS Growth
N/A
100.00
EPS
0.90
N/A
Revenue
$2,068,421,000.00
$49,590,000.00
Revenue This Year
N/A
$34.37
Revenue Next Year
N/A
$22.86
P/E Ratio
$39.59
N/A
Revenue Growth
14.07
142.67
52 Week Low
$30.16
$4.26
52 Week High
$55.74
$10.08

Technical Indicators

Market Signals
Indicator
PZZA
XERS
Relative Strength Index (RSI) 45.02 58.17
Support Level $30.47 $6.26
Resistance Level $34.89 $6.41
Average True Range (ATR) 1.41 0.20
MACD -0.29 0.03
Stochastic Oscillator 9.04 82.77

Price Performance

Historical Comparison
PZZA
XERS

About PZZA Papa John's International Inc.

Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: